Literature DB >> 27543594

Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility.

Barbora Brodská1, Petra Otevřelová1, Kateřina Kuželová2.   

Abstract

The expression on the surface of tumor cells of ligands for the PD-1 inhibitory receptor prevents the antitumor immune response and is considered to be a negative prognostic factor in a variety of solid tumors as well as in hematologic malignancies. To determine if it were possible to analyze PD-L1 with PCR-based methods, we assessed the expression of PD-L1 in primary samples from patients with acute myeloid leukemia, in healthy donors, and in a panel of cell lines, by means of flow cytometry, RT-PCR, and Western blotting. Although the surface density of the protein was not correlated with the amount of expressed full-length mRNA, we found a statistically significant positive correlation between PD-L1 surface density and the ratio of two transcript variants (variant 1/variant 2). Our PCR-based method allows for retrospective examination of PD-L1 surface expression from frozen cDNA samples, without the need for a reference gene. Our results also suggest that variant 2, which is produced by alternative splicing, negatively regulates PD-L1 protein expression on the cell surface. In addition, PD-L1 exposition on the cell surface is clearly associated with a shift of electrophoretic mobility, observed on Western blots. This finding can explain the relatively large variability in PD-L1 apparent molecular weight reported in the literature and offers an alternate means for the assessment of PD-L1 surface expression. Cancer Immunol Res; 4(10); 815-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27543594     DOI: 10.1158/2326-6066.CIR-16-0063

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  4 in total

1.  Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma.

Authors:  Akinori Nukui; Yoshiaki Yanai; Toyonori Tsuzuki; Hideyuki Abe; Kyoko Arai; Ken-Ichiro Yoshida; Takao Kamai
Journal:  Oncotarget       Date:  2017-12-25

2.  High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.

Authors:  Barbora Brodská; Petra Otevřelová; Cyril Šálek; Ota Fuchs; Zdenka Gašová; Kateřina Kuželová
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

3.  NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia.

Authors:  Kateřina Kuželová; Barbora Brodská; Jana Marková; Martina Petráčková; Johannes Schetelig; Šárka Ransdorfová; Zdenka Gašová; Cyril Šálek
Journal:  Oncoimmunology       Date:  2022-05-06       Impact factor: 7.723

4.  Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.

Authors:  Yating Tang; Guang Li; Shan Wu; Lingrong Tang; Ning Zhang; Jinzhao Liu; Shuo Zhang; Lei Yao
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.